| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
26,320,000 |
| Market
Cap: |
3.83(M) |
| Last
Volume: |
169,426 |
Avg
Vol: |
168,964 |
| 52
Week Range: |
$0.1454 - $0.1454 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Related Products |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Navidea Biopharmaceuticals is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Co. is developing multiple precision-targeted products based on its Manocept™ platform to improve patient care by identifying the sites and pathways of undetected disease and enable diagnostic, clinical decision-making and targeted treatment. Co.'s business is focused on two primary types of drug products: diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and therapeutic development programs, including therapeutic applications of its Manocept platform.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Goldberg Michael M |
Director |
• • – |
2014-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
180,241 |
|
- |
|
| Troup Gordon A |
Director |
• • – |
2014-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
166,250 |
|
- |
|
| Drake Peter F |
Director |
• • – |
2014-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
59,250 |
|
- |
|
| Larson Brent L |
EVP, CFO, Treas & Secy |
• • – |
2014-01-07 |
4 |
D |
$1.93 |
$66,214 |
D/D |
(34,308) |
322,996 |
|
- |
|
| Larson Brent L |
EVP, CFO, Treas & Secy |
• • – |
2014-01-07 |
4 |
OE |
$0.30 |
$21,000 |
D/D |
70,000 |
357,304 |
|
- |
|
| Goldberg Michael M |
Director |
• • – |
2013-11-18 |
4 |
A |
$0.00 |
$0 |
D/D |
12,250 |
160,241 |
|
- |
|
| Platinum Partners Value Arbitrage Fund, Lp |
10% Owner |
– – • |
2013-11-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,073,375 |
|
- |
|
| Goldberg Michael M |
Director |
– • – |
2013-11-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
147,991 |
|
- |
|
| Troup Gordon A |
Director |
• • – |
2013-11-08 |
4 |
B |
$1.36 |
$27,158 |
D/D |
20,000 |
146,250 |
2.39 |
- |
|
| Cope Frederick O |
SVP |
• • – |
2013-11-08 |
4 |
B |
$1.43 |
$5,005 |
D/D |
3,500 |
90,814 |
2.74 |
- |
|
| Pykett Mark Jerome |
CEO |
• • – |
2013-11-08 |
4 |
B |
$1.35 |
$14,715 |
D/D |
10,900 |
402,674 |
2.81 |
- |
|
| Larson Brent L |
EVP, CFO, Treas & Secy |
• • – |
2013-11-08 |
4 |
B |
$1.39 |
$6,950 |
D/D |
5,000 |
287,304 |
2.74 |
- |
|
| Ford Brendan A |
Director |
• • – |
2013-11-08 |
4 |
B |
$1.45 |
$29,000 |
D/D |
20,000 |
139,250 |
2.39 |
- |
|
| Pykett Mark Jerome |
Pres. & CEO |
• • – |
2013-03-15 |
4 |
B |
$2.70 |
$4,995 |
D/D |
1,850 |
355,914 |
2.73 |
- |
|
| Troup Gordon A |
Director |
• • – |
2013-03-15 |
4 |
B |
$2.70 |
$18,893 |
D/D |
7,000 |
126,250 |
2.39 |
- |
|
| Ford Brendan A |
Director |
– • – |
2013-03-15 |
4 |
B |
$2.71 |
$13,550 |
D/D |
5,000 |
119,250 |
2.39 |
- |
|
| Tulip Thomas H. |
EVP & Chief Business Officer |
• – – |
2013-03-15 |
4 |
B |
$2.82 |
$49,350 |
D/D |
17,500 |
45,000 |
2.74 |
- |
|
| Regan William J. |
SVP-Global Regulatory Strategy |
• – – |
2013-03-15 |
4 |
B |
$2.71 |
$13,550 |
D/D |
5,000 |
5,000 |
2.74 |
- |
|
| Pykett Mark Jerome |
Pres. & CEO |
• • – |
2013-03-13 |
4/A |
D |
$3.16 |
$184,234 |
D/D |
(58,302) |
389,924 |
|
- |
|
| Pykett Mark Jerome |
Pres. & CEO |
• • – |
2013-03-13 |
4/A |
A |
$0.00 |
$0 |
D/D |
175,000 |
448,226 |
|
- |
|
| Rowinsky Eric K |
Director |
• • – |
2013-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
134,250 |
|
- |
|
| Ford Brendan A |
Director |
• • – |
2013-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
114,250 |
|
- |
|
| Troup Gordon A |
Director |
• • – |
2013-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
119,250 |
|
- |
|
| Cope Frederick O |
SVP |
• • – |
2013-03-13 |
4 |
D |
$3.16 |
$134,888 |
D/D |
(42,686) |
87,314 |
|
- |
|
| Cope Frederick O |
SVP |
• • – |
2013-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
130,000 |
|
- |
|
411 Records found
|
|
Page 9 of 17 |
|
|
